Navigation Links
Profil Institute's CEO Presenting on Early Phase Clinical Research in India
Date:1/27/2011

SAN DIEGO, Jan. 27, 2011 /PRNewswire/ -- Profil™ Institute for Clinical Research, Inc., a company leading the industry in early phase clinical trials for diabetes and obesity, announced today that CEO Dr. Marcus Hompesch is an invited speaker at the Ramanbhai Foundation 5th International Symposium and ISCR's 4th Annual Clinical Research Conference in February.  

The Ramanbhai Foundation's International Symposium will be held February 1-4 in Ahmedabad, India and is hosted by the Zydus Research Center, the research arm of Indian pharmaceutical company Zydus Cadila. The symposium's speakers include world-leading scientists from academia and the pharmaceutical industry specializing in drug research and development for cancer, inflammation, and cardio-metabolic diseases.  Profil Institute's Dr. Hompesch will speak on the topic of selecting the appropriate target populations for early phase clinical research and first in human studies of diabetes drugs.

Dr. Hompesch will also present at the Indian Society for Clinical Research's (ISCR) 4th Annual Clinical Research Conference held February 11-12 at the Crowne Plaza Hotel in Gurgaon, India.  The conference's focus is strengthening India's domestic clinical research industry through best practices, stricter regulatory standards and global partnerships.  Dr. Hompesch will present on the topic of early clinical development in India and its proof of concept in diabetes.  

"Historically India's pharmaceutical companies have focused on providing outsourcing and on competitive manufacturing of generics, APIs, and chemicals used in the manufacturing of drugs," said Dr. Marcus Hompesch, Profil Institute CEO.  "However, healthcare has become a key priority for the Indian government, and we are now seeing a paradigm shift as India strives to bolster its position in the pharmaceutical and clinical research industry as a global partner, innovator and competitor."

India's private sector is eager for outside partnerships. Profil Institute has become an advisor to Indian companies building the capabilities and establishing stricter standards to perform clinical trials, and, in what is a turn of traditional roles, Profil is seeing Indian companies begin to outsource early phase clinical trials in diabetes to Profil Institute in the US.

Dr. Hompesch continued, "Diabetes is a rapidly growing chronic disease in India.  According to a recent analysis by PricewaterhouseCoopers titled Pharma 2020, it is estimated that the number of Indians with diabetes is projected to reach 73.5 million in 2025 and the number of clinical trials in general in India are expected to grow 25-30 percent annually.  India's needs and participation in the global pharmaceutical industry must not be ignored."    

More information about Dr. Hompesch's presentations at these and other conferences is available on Profil Institute's website at www.profilinstitute.com/News/ResearchNews.

About Profil™ Institute for Clinical Research, Inc.

Profil Institute is world-renowned as a Center of Excellence for diabetes and obesity early phase clinical research.  The company's advances in early phase drug research and its specific focus on diabetes, obesity and cardio-metabolic diseases as it relates to the diabetic patient population have led Profil Institute to be the most highly regarded clinical research institute for early phase diabetes drug trials.  

To date, Profil Institute has been involved with almost every clinically promising drug category and device development in diabetes and in more than 140 clinical studies since the company's inception in 2004. Contributing to Profil Institute's success is that the company is recognized as the leader in automated glucose clamps, considered the "Gold Standard" for the evaluation of anti-diabetic drugs and devices.  The company's key scientists hail from academic centers including the WHO Collaborating Center of Diabetes at the Heinrich-Heine University of Düsseldorf, Columbia University, University of Michigan and Harvard University.

For more information visit www.profilinstitute.com.


'/>"/>
SOURCE Profil Institute for Clinical Research, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Reportlinker Adds Teva Pharma. Industries Ltd: PharmaVitae Profile
2. Reportlinker Adds CSL Limited: PharmaVitae Profile
3. Reportlinker Adds UCB S.A.: PharmaVitae Profile
4. Reportlinker Adds Watson Pharmaceuticals Inc.: PharmaVitae Profile
5. Reportlinker Adds H. Lundbeck A/S: PharmaVitae Profile
6. Reportlinker Adds Daiichi Sankyo Co., Ltd: PharmaVitae Profile
7. Reportlinker Adds Merck & Co., Inc.: PharmaVitae Profile
8. Reportlinker Adds Shire plc: PharmaVitae Profile
9. Reportlinker Adds Novo Nordisk A/S: PharmaVitae Profile
10. Reportlinker Adds Boehringer Ingelheim GmbH: PharmaVitae Profile
11. Reportlinker Adds Sanofi-Aventis: PharmaVitae Profile
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/11/2017)... , May 11, 2017  Thornhill Research Inc. ... been awarded an $8,049,024 USD five-year, firm-fixed-priced, indefinite-quantity/indefinite-delivery ... the Canadian Commercial Corporation (CCC) ( Ottawa, ... Systems to administer general anesthesia to patients requiring ... "The US Marine Corps have been a ...
(Date:5/10/2017)... -- The Corporate Whistleblower Center says, "We are urging ... to call us anytime at 866-714-6466 if they possess ... a substantial scheme to overbill Medicare. We are ... of a medical equipment company if their employer ... practice groups with extra generous incentives to use, or ...
(Date:5/9/2017)... WARSAW, Ind. , May 9, 2017 ... global leader in musculoskeletal healthcare, today announced it has ... Large Employers of 2017" list. The Company was ranked ... categories of Large Employers and Healthcare Equipment and Services. ... U.S. employers based on an anonymous, independent survey of ...
Breaking Medicine Technology:
(Date:5/26/2017)... (PRWEB) , ... May 26, 2017 , ... Mediaplanet is ... Wound Care" campaign in USA Today, which will educate readers on how to take ... the campaign, a large focus is placed on melanoma. Dancing with the Stars professional, ...
(Date:5/26/2017)... Calif. (PRWEB) , ... May 26, 2017 , ... ... the integration of the CareFusion NOX-T3 portable sleep monitor with its Somnoware Sleep ... a consistent, browser-based interface for diagnostic device operations. With this platform, initializing devices ...
(Date:5/26/2017)... ... 26, 2017 , ... After raising nearly $30,000 on Kickstarter , about ... available at a discounted crowdfunding price on Indiegogo . , “Along with creating ... wanted to bring a fidget toy to the market that was made of superior ...
(Date:5/26/2017)... ... ... “When the Stars Lead Home”: a poignant story of loss, determination, and ... Douglas, an avid reader who lives in the Pacific Northwest with her husband, daughter, ... Adventure Camp. She couldn’t be more grateful. , Twelve-year old Tizzy could not believe ...
(Date:5/26/2017)... ... , ... Water damage to the flooring of several classrooms at The Fort ... with a number of critical issues to address before students could return to classes. ... little or no disruption to class schedules. Second, the project had to comply with ...
Breaking Medicine News(10 mins):